Results 81 to 90 of about 111,189 (247)

Rituximab

open access: yesReactions Weekly, 2006
europepmc   +2 more sources

Rituximab for TTP [PDF]

open access: yesAmerican Journal of Hematology, 2005
Sarah M, Scott   +1 more
openaire   +2 more sources

Distinct Systemic Sclerosis Phenotypes Related to Ethnicity: An Opportunity to Personalize Care?

open access: yesArthritis Care &Research, EarlyView.
Objective The objective is to describe and compare demographic, clinical, and serological characteristics of patients with systemic sclerosis (SSc) according to ethnic background. Methods Participants enrolled in the Canadian Scleroderma Research Group cohort who self‐identified to a single ethnicity group were included.
Danick Goulet   +11 more
wiley   +1 more source

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

open access: yesArthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato   +27 more
wiley   +1 more source

Association of Elevated Platelets and C‐Reactive Protein With Severe Disease and Poor Survival in Systemic Sclerosis

open access: yesArthritis Care &Research, EarlyView.
Objective Elevated C‐reactive protein (CRP) levels in systemic sclerosis (SSc) have been linked with severe disease and worse survival, but the role of platelet levels remains unclear. This study examined whether elevated platelet levels, CRP levels, or both are associated with disease severity, progression, and survival in SSc.
Brian S. Lee   +4 more
wiley   +1 more source

Efficacy of high‐frequency low‐dose rituximab and acalabrutinib in chronic lymphocytic leukemia

open access: yesHemaSphere
Anti‐CD20 monoclonal antibodies (mAbs) are effective but not curative treatment for chronic lymphocytic leukemia (CLL). To study rituximab efficacy, we examined serial blood samples from CLL patients receiving initial monotherapy with high‐frequency low ...
Charles C. Chu   +11 more
doaj   +1 more source

Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell Development

open access: yesClinical and Developmental Immunology, 2008
We describe the effect on the neonate of administration of rituximab to a woman with idiopathic thrombocytopenic purpura (ITP). Rituximab, an anti-CD20 antibody, was given weekly for 4 weeks to a woman with ITP in her third trimester of pregnancy.
D. T. Klink   +3 more
doaj   +1 more source

Clinician and patient factors associated with long‐term glucocorticoid use in people with rheumatoid arthritis on advanced therapies

open access: yesArthritis Care &Research, Accepted Article.
Background Despite guideline recommendations, long‐term glucocorticoid (GC) use is common in rheumatoid arthritis (RA). We conducted a clinician survey nested within a large registry to identify patient and clinician factors associated with GC use. Methods Clinicians contributing patients to the CorEvitas Rheumatoid Arthritis registry were surveyed ...
Michael D. George   +7 more
wiley   +1 more source

Impact of Six‐Month Monitoring Compared to Three‐Month Monitoring of Laboratories During Methotrexate Therapy

open access: yesArthritis Care &Research, EarlyView.
Objective To evaluate whether extending the American College of Rheumatology–recommended monitoring interval for complete blood count and liver function tests in patients receiving methotrexate (MTX) affects timely detection of medication‐related toxicity.
Spencer Simko   +4 more
wiley   +1 more source

Employment Trajectories of Patients with Systemic lupus erythematosus (SLE) and Factors Driving Transitions Between States

open access: yesArthritis Care &Research, Accepted Article.
Objective Systemic lupus erythematosus (SLE) significantly impacts employment capacity. This study aimed to investigate the impact of burden of disease activity, damage, and treatment on employment outcomes and transitions in patients with SLE. Materials and Methods Using data from a single center, we analyzed employment transitions, adjusted mean ...
Javier Mencia‐Ledo   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy